





(An Aurobindo Pharma Company)

August 2026



Aurobindo Pharma

Overview of our parent company



Aurobindo Pharma

Our global footprint

Global Subsidiaries

NORTH AMERICA

- USA
- Canada
- Mexico

SOUTH AMERICA

- Brazil
- Colombia

EUROPE


- United Kingdom
- France
- Portugal
- The Netherlands
- Germany
- Spain
- Italy
- Poland
- Belgium
- Malta

ASIA

- India
- Hong Kong
- Japan
- Singapore
- South Korea
- Thailand
- Vietnam
- Indonesia


AFRICA

- South Africa
- Ethiopia
- Kenya
- Nigeria
- Tanzania



References:

Global Presence: <https://www.aurobindo.com/about-us/at-a-glance/global-operations-map>
<https://www.aurobindo.com/investors/results-reports-presentations/results-announcements>



Introduction and Company Review



Who we are

- Wholly owned subsidiary of Aurobindo Pharma
- Headquartered in Hyderabad, India
- We develop and manufacture biosimilars for global markets (One Product – One Quality)



Team

- Leadership team comprises of PhDs with working experience from global biologics and biosimilar companies in the EU and US



Manufacturing footprint

- Mammalian bio-bulk manufacturing
- Microbial bio-bulk manufacturing
- Vials and pre-fillable syringes filling
- Drug product packaging

**EU, ANVISA, and WHO
certified GMP facility**



Vision and Mission

Our vision is to improve the wellbeing of patients suffering from debilitating illnesses by providing them with access to high quality and cost-effective biosimilars

Deliver exceptional value to stakeholders and better health for patients by becoming a leading global biosimilar developer by 2030



Build deep capabilities in development and manufacturing to deliver quality and cost-effective biosimilars for patients across the globe




Create a sustainable and broad portfolio of biosimilars with a focus on oncology and immunology therapies



Improving access to biosimilars for patients across the globe



Our Journey



Business strategy offers long term value creation and differentiation opportunity



Arenas

Where will the business be active?

- ✓ Focus on Oncology and Immunology biosimilars
- ✓ Focus on US, EU5, UK, Canada and certain emerging markets
- ✓ Proven template of delivering 100% hit rate in clinical studies and product filings leading to approvals

Vehicles

How will we get there?

- ✓ Robust pipeline of 15 biosimilars
- ✓ Three submissions in 2026, including first filings with FDA in 2026

Staging and Pacing

What will be the speed of our moves, product launches and key initiatives?

- ✓ Four products approved in Regulated Markets
- ✓ Commercialization began from CY 2025/26
- ✓ More launches in EEA in 2026
- ✓ Filings in other regulated and emerging markets to continue

Differentiators

How do we intend to differentiate and win?

- ✓ Operating efficiency through strategically co-located R&D and manufacturing
- ✓ Clinical efficiency through innovative study designs pushing regulatory barriers
- ✓ 'One product for All' approach
- ✓ CuraTeQ set up for the long term as a 'global biosimilar' player

Economic Logic

10-year vision to 2035 with a strategically constructed pipeline of biosimilars addressing >\$50Bn branded biologics opportunity

Holistic Approach Towards Success



Cell Line Development

- Reliable and tested CHO-GS platform – a definitive advantage



Process & Product Development

- Strong process development know-how
- Analytical methods – Totality of evidence approach
- Orthogonal approaches to dissect residual uncertainty



Product Manufacturing

- Fully integrated end-to-end capacity footprint to ensure continuity of operations and supply
- Equipped with infrastructure compliant with cGMP and global quality guidelines



Clinical Development

- In-house expertise to design and conduct PK similarity and clinical efficacy safety studies, with program management, biostatistics and medical writing expertise



Regulatory & IPM

- In-house IP and regulatory teams with experience in handling global product filings
- Strong network of regulatory and IP consultants



Commercial

- Product launches initiated in Europe, UK, LATAM, and India
- Geared for product launches in other regulated, semi regulated, and emerging markets

R&D Capabilities

World class laboratories for biopharmaceutical development



Over 125+ scientists (PhD to Masters ratio of 1:5) with expertise in clone, process, and method development for small proteins to complex monoclonal antibodies



Cell line development and translational sciences



In vitro functional characterization - functional bioassays, ELISA, SPR, BLI, Flow Cytometry based target binding studies, signalling studies to determine functional quality attributes



Mammalian and microbial product development including scale-down model development, process characterization, and process scale-up capabilities



Capability to fully characterize a product with >50 structural, physicochemical, and functional attributes




Analytical method development (both analytical and functional) for mAbs, GLP1s, short and long peptides, formulation development, and stability studies



Manufacturing Capabilities

Fully integrated EU GMP certified facility



CuraTeQ's Biosimilars Pipeline Status

Brand Name	Product Name	Therapeutic Segment	Clinical	Filing	Approval	Launch
DYRUPEG	Pegfilgrastim	Oncology			☑ EMA, MHRA, HC	☑
ZEFYLT	Filgrastim				☑ EMA, MHRA	☑
BEVQOLVA*	Bevacizumab			Phase 3 ongoing	☑ MHRA, HC, CDSCO	☑
DAZUBLYS	Trastuzumab				☑ EMA, MHRA, CDSCO	☑
FUGEVY# FILVIZY	Denosumab				Ph3 Successful; EMA Filing completed	
OMAZIJEV	Omalizumab	Respiratory			Ph3 Successful; Filing in Q3 2026	
BP08	Tocilizumab	Autoimmune		Pivotal study complete		
BP05	Ranibizumab	Ophthalmology		Phase 3 ongoing		
BP58	Trastuzumab S.C.	Oncology		Phase 1 in FY 2026		
BP27	Undisclosed			Preclinical dev. complete		
BP25	Undisclosed			Under development		

* MHRA and HC approval granted with PK study


Also being developed for Orthopedic indication (**Fugevy**)

Key Next-Wave Products to Sustain Momentum

Product Code	Key Indications	2025 Revenue (est.)	Global Market Opportunity (est.)* by 2030
BP31	Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis	\$6.7B	\$9.5B
BP36	Atopic Dermatitis, Asthma	\$13.1B	\$22.0B
BP30	Multiple Myeloma	\$14.4B	\$16.0B
BP45	Ulcerative Colitis, Crohn's Disease, Plaque Psoriasis, Psoriatic Arthritis	\$17.6B	\$20.0B
BP51	Ulcerative Colitis, Crohn's Disease, Plaque Psoriasis, Psoriatic Arthritis	\$4.2B	\$5.8B
BP29	Multiple Sclerosis	\$7.2B	\$6.5B
BP41	Lung Cancer (NSCLC, ES-SCLC), Hepatocellular Cancer, Melanoma	\$4.4B	\$8.0B
BP50	Lung Cancer (NSCLC, ES-SCLC), Endometrial Cancer, Bladder Cancer	\$5.9B	\$8.0B

**Cited from Various Market Research Reports*

APPROVED PRODUCTS



ZEFYLT[®]

Filgrastim biosimilar




ZEFYLT[®]
has received **EMA** and **MHRA**
marketing authorization




Medicines &
Healthcare products
Regulatory Agency

DYRUPEG[®]

Pegfilgrastim biosimilar




DYRUPEG[®]
has received **EMA**,
MHRA, and
Health Canada
marketing
authorization




Medicines &
Healthcare products
Regulatory Agency



APPROVED PRODUCTS



BEVQOLVA®

Bevacizumab biosimilar



BEVQOLVA®
has received **MHRA, HC,** and
CDSCO marketing authorization



Medicines &
Healthcare products
Regulatory Agency



Health
Canada



DAZUBLYS®

Trastuzumab biosimilar



DAZUBLYS®
has received **EMA,**
MHRA, and **CDSCO**
marketing authorization



EUROPEAN MEDICINES AGENCY



Medicines &
Healthcare products
Regulatory Agency



*440 mg SKU developed for India and
emerging markets.



CDMO Services

Contract Manufacturing Services (CMO) Biologics



Biologics CMO in Hyderabad for clinical and commercial drug substance and drug product manufacturing



End-to-end product development capabilities
(Process optimization and characterization, and scale-up)



4x15 KL mammalian cell culture bioreactors (60 KL cumulative capacity);
Also initiated expansion of drug substance manufacturing capacity to 120 KL,
set to complete by 2030.



Isolator based drug product filling lines



Fully equipped MSAT labs




End-to-End digital and automated operations;
AI/ML powered enterprise data lake and analytics platforms - available for
data exchange with client data lakes

SAP S/4 HANA


Veeva Vault QMS

PAS | X






Synthesizing Therapeutic Peptides



Focus Therapeutic segments

Oncology, Diabetology, and Gastroenterology



Platform technology

Solid Phase Peptide Synthesis (SPPS), Liquid Phase Peptide Synthesis (LPPS), and Hybrid approaches



Manufacturing capabilities

Five cGMP manufacturing lines with annual production capacities to generate ~25 kg of APIs



Development pipeline

15 API DMFs filed with US FDA; 2 more peptides under development

API DMF submissions contributed to



8 ANDA Approvals

Vasopressin, Icatibant acetate, Linaclotide, Leuprolide acetate, Etelcalcetide hydrochloride, Desmopressin acetate, Calcitonin salmon, and Ganirelix acetate



2 EDQM CEP

Desmopressin acetate, Octreotide acetate



Facility inspected and certified by US FDA, WHO, CDSCO

Peptides APIs & Approvals

Peptide API	Therapeutic Segment	DMF status (US FDA)
Vasopressin	Gastroenterology, Nephrology	Approved
Icatibant acetate	Dermatology	Approved
Leuprolide acetate	Oncology, Gynaecology	Approved
Linaclotide	Gastroenterology	Approved
Etelcalcetide HCl	Nephrology, Endocrinology	Approved
Desmopressin acetate	Endocrinology, Anti-Diabetics	Approved
Calcitonin salmon	Orthopaedics, Women's Health	Approved
Ganirelix acetate	Antiretroviral therapy, Gynaecology	Approved
Degarelix	Oncology	Filed, Under Review
Glatiramer acetate	Auto-immune, Rheumatology	Filed
Plecanatide	Gastroenterology	Filed, Under Review
Teriparatide	Orthopaedics, Women's Health	Filed
Octreotide acetate	Gastroenterology, Oncology, Neuroendocrinology	Filed, Under Review
Liraglutide	Endocrinology, Anti-Diabetics	Filed
Semaglutide	Endocrinology, Anti-Diabetics	Filed



Contract Development and Manufacturing (CDMO) Services



Custom Synthesis Capabilities

- **Peptide API** synthesis and purification (solid / liquid phase, and hybrid approaches)
- **Oligonucleotide** synthesis with full range of chemistry and manufacturing services
- **Impurity** synthesis and characterization
- **Linker and Payload** synthesis
- Pre-clinical, clinical and commercial manufacturing (gram to kilogram scales)

Our Strengths

- Extensive experience in peptide API development and manufacturing
- Strong capabilities in analytical, upstream, and downstream processing technologies



Regulatory Compliance

Facilities compliant with US FDA standards



Capacity

High-capacity mfg. facility for peptides & oligonucleotides



Expertise


Highly experienced and skilled human resources



CuraTeQ

Expanding access. Healing lives.

THANK YOU



Expanding access. Healing lives.

www.curateqbio.com